As of 2024-12-12, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is 77.98. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 13,006.95 mil USD. SRPT's TTM EBITDA according to its financial statements is 166.81 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 17.8x | 16.0x |
| Forward P/E multiples | 16.0x - 23.4x | 16.8x |
| Fair Price | 14.23 - 30.15 | 17.86 |
| Upside | -88.7% - -76.0% | -85.8% |
| Date | EV/EBITDA |
| 2024-12-06 | 79.57 |
| 2024-12-05 | 78.49 |
| 2024-12-04 | 78.63 |
| 2024-12-03 | 78.33 |
| 2024-12-02 | 79.44 |
| 2024-11-29 | 82.53 |
| 2024-11-27 | 85.16 |
| 2024-11-26 | 80.90 |
| 2024-11-25 | 71.83 |
| 2024-11-22 | 71.59 |
| 2024-11-21 | 69.45 |
| 2024-11-20 | 69.66 |
| 2024-11-19 | 67.23 |
| 2024-11-18 | 66.11 |
| 2024-11-15 | 66.04 |
| 2024-11-14 | 68.65 |
| 2024-11-13 | 70.58 |
| 2024-11-12 | 71.64 |
| 2024-11-11 | 73.65 |
| 2024-11-08 | 75.81 |
| 2024-11-07 | 75.13 |
| 2024-11-06 | 79.45 |
| 2024-11-05 | 77.76 |
| 2024-11-04 | 76.65 |
| 2024-11-01 | 76.77 |
| 2024-10-31 | 78.33 |
| 2024-10-30 | 79.35 |
| 2024-10-29 | 80.74 |
| 2024-10-28 | 80.77 |
| 2024-10-25 | 81.27 |
| 2024-10-24 | 81.77 |
| 2024-10-23 | 80.55 |
| 2024-10-22 | 79.71 |
| 2024-10-21 | 79.08 |
| 2024-10-18 | 78.94 |
| 2024-10-17 | 77.32 |
| 2024-10-16 | 78.28 |
| 2024-10-15 | 77.03 |
| 2024-10-14 | 77.39 |
| 2024-10-11 | 77.47 |
| 2024-10-10 | 76.27 |
| 2024-10-09 | 73.74 |
| 2024-10-08 | 74.73 |
| 2024-10-07 | 73.62 |
| 2024-10-04 | 75.12 |
| 2024-10-03 | 74.18 |
| 2024-10-02 | 76.33 |
| 2024-10-01 | 76.22 |
| 2024-09-30 | 77.69 |
| 2024-09-27 | 77.48 |